deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05511922

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

A Pharmacokinetic Subtrial in Adolescent Patients With Hereditary Angioedema Type I or II Participating in the KVD900-302 Trial

Sponsor: KalVista Pharmaceuticals, Ltd.

Conditions Hereditary Angioedema
Interventions Drug: KVD900 300 mg KVD900 600 mg
Updated 21 times since 2022 Last updated: Jul 17, 2025 Started: Oct 24, 2022 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Hereditary Angioedema, this trial is ongoing. The trial is conducted by KalVista Pharmaceuticals, Ltd. and has accumulated 21 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Aug 2023 · 2 months · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Aug 2025 · 6 months · monthly snapshot~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Aug 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  3. Feb 2025 — Aug 2025 [monthly]

    Recruiting PHASE3

  4. Sep 2024 — Feb 2025 [monthly]

    Recruiting PHASE3

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

▶ Show 16 earlier versions

  1. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE3

  2. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE3

  3. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE3

  4. Jan 2024 — Mar 2024 [monthly]

    Recruiting PHASE3

  5. Nov 2023 — Jan 2024 [monthly]

    Recruiting PHASE3

  6. Oct 2023 — Nov 2023 [monthly]

    Recruiting PHASE3

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE3

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE3

  9. Jun 2023 — Aug 2023 [monthly]

    Recruiting PHASE3

  10. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE3

  11. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE3

  12. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE3

  13. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE3

  14. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  15. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  16. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • KalVista Pharmaceuticals, Ltd.
Data source: KalVista Pharmaceuticals, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Athens, Greece , Auckland, New Zealand , Barcelona, Spain , Berlin, Germany , Birmingham, United Kingdom , Cambridge, United Kingdom , Campbelltown, Australia , Cape Town, South Africa , Cardiff, United Kingdom and 47 more locations